Regenxbio (RGNX) Equity Ratio (2014 - 2025)

Regenxbio's Equity Ratio history runs 12 years deep, the most recent figure standing at 0.23 for Q4 2025.

• In Q4 2025, Equity Ratio fell 59.3% year-over-year to 0.23; the TTM figure through Dec 2025 stood at 0.23 (down 59.3% YoY), while the FY2025 annual figure was 0.23, down 59.3% from the prior year.
• Equity Ratio was 0.23 for Q4 2025 at Regenxbio, down from 0.31 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.69 in Q4 2021 to a low of 0.23 in Q4 2025.
• Historically, Equity Ratio has averaged 0.56 across 5 years, with a median of 0.6 in 2021.
• The sharpest annual moves came in 2021 and 2025: Equity Ratio advanced 28.63% in 2021, then sank 59.3% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.69 in 2021, then declined by 9.72% to 0.62 in 2022, then fell by 12.32% to 0.54 in 2023, then gained by 2.59% to 0.56 in 2024, then sank by 59.3% to 0.23 in 2025.
• The last three Equity Ratio figures came in at 0.23 (Q4 2025), 0.31 (Q3 2025), and 0.37 (Q2 2025), per Business Quant data.